Genmab A/S (0MGB)
LSE
Real-time Data
07:00 AM
Day's Range
2,111.0052 wk Range
1,514.50Overview - 0MGB - Genmab A/S
Key Statistics
Valuation
Enterprise Value
108.10B
P/E (Trailing)
‪30.64‬
PEG Ratio
‪-3.33‬
Price / Sales (TTM)
‪10.61‬
Price / Book
‪4.92‬
EV / EBITDA
‪15.59‬
Profitability
Gross Margin
‪92.72%‬
Profit Margin
‪29.01%‬
Operating Margin
‪40.13%‬
Return on Assets
‪13.80%‬
Return on Equity
‪17.84%‬
Ownership
Shares Outstanding
62.35M
Float
64.47M
Held by Insiders
‪0.00%‬
Held by Institutions
‪49.98%‬
Price stats
Beta
‪0.64‬
50-Day Avg
‪1,856.41‬
200-Day Avg
‪1,865.05‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - 0MGB - Genmab A/S
Peers - 0MGB - Genmab A/S
Peer Comparison
Compared with companies in Biotechnology listed on LSE.
- 0MGBLSEGenmab A/S168.24BMarket Cap+25.25%52-week change30.65P/E (Trailing)‪29.01%‬Profit Margin
- 0QZULSEVertex Pharmaceuticals Incorporated140.31BMarket Cap+29.11%52-week change0.58P/E (Trailing)‪34.99%‬Profit Margin
- 0R2MLSERegeneron Pharmaceuticals, Inc.90.49BMarket Cap+30.71%52-week change0.12P/E (Trailing)‪27.86%‬Profit Margin
- 0A45LSEModerna, Inc.66.31BMarket Cap+81.03%52-week change55.34P/E (Trailing)‪11.32%‬Profit Margin
- 0QW0LSEargenx SE51.17BMarket Cap+30.71%52-week change41.26P/E (Trailing)‪-47.51%‬Profit Margin
- 0NZTLSEUCB SA44.92BMarket Cap+9.88%52-week change127.93P/E (Trailing)‪6.45%‬Profit Margin
- 0K91LSENorthern Trust Corporation41.29BMarket Cap+29.70%52-week change0.26P/E (Trailing)‪24.67%‬Profit Margin
Profile Summary - 0MGB - Genmab A/S
About
Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, specializing in the discovery and development of antibody-based therapeutics primarily for cancer and other serious diseases. Founded in 1998, it focuses on innovative human antibody technologies to create differentiated products that address…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
